OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.
Objective: To validate the OPTIMIPARK questionnaire as a tool to help the clinician in the adjustment of dopaminergic treatment in Parkinson´s disease(PD). Background: At early…Influence of Dopamine Transporter Gene Polymorphism on Wearing Off
Objective: To study the influence of Dopamine transporter gene polymorphism on Wearing off (WO) through 19 items wearing off questionnaire (WOQ-19) Background: The dopamine transporter…Parkinson’s Disease Medication Safety in the Inpatient Cohort of a Tertiary Centre
Objective: Our study aimed to determine the accuracy of initial prescribing on hospital admission and the subsequent timing of administration of Parkinson’s disease (PD) medications…The responsiveness of arm swing to dopaminergic medication in Parkinson’s disease depends on task complexity
Objective: The aim of this study is to analyse the responsiveness of arm swing during walking to dopaminergic medication in patients with Parkinson’s disease. Background:…Levodopa Changes Functional Connectivity Patterns in Subregions of the Primary Motor Cortex in Patients with Parkinson’s Disease
Objective: To investigated functional connectivity pattern changes in M1 subregions and relationships to improved clinical symptoms following levodopa administration. Background: The primary motor cortex (M1)…The role of dopamine mis-metabolism in preclinical Parkinson’s disease olfactory deficits
Objective: To gain an understanding of the underlying pathological mechanisms of Parkinson’s disease (PD)-related hyposmia using post-mortem human olfactory bulbs and an in vivo model…Characterization of striatal dopaminergic neurotransmission in the rat pre-formed fibril models of Parkinson’s disease
Objective: To determine the longitudinal effects of synucleinopathy and synucleinopathy-triggered nigrostriatal degeneration on basal and evoked striatal dopamine (DA) release in the striatum at 4…Increased risk of Parkinson’s disease in patients with schizophrenia spectrum disorders
Objective: To investigate the coincidence of Parkinson’s disease (PD) and schizophrenia spectrum disorders (SCD). Background: PD is characterized by a progressive loss of mesostriatal dopamine…Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease
Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson’s disease
Objective: To report 18-month safety and clinical outcomes from a phase 1, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor fluctuations.…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 26
- Next Page »